Resverlogix Announces FDA Confirmation Regarding Filing Pathway for Apabetalone
CALGARY, Alberta, June 14, 2018 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that it has received confirmation from the U.S. Food and Drug Administration ("FDA") that BETonMACE, Resverlogix's on-going Phase 3 study, if successful, is likely to support the filing and approval of a New Drug Application ("NDA"). The statistical analysis plan and endpoints proposed by the Company were reviewed and accepted by the Division of Cardiovascular and Renal Products ("DcaRP") of the FDA. The exact indication to be sought by the Company, and to be reviewed by the FDA, would be driven by the study's results.
The ongoing Phase 3 BETonMACE trial has enrolled its planned target of over 2,400 patients. The trial patients are high-risk cardiovascular disease ("CVD") patients with type 2 Diabetes Mellitus ("DM") and low levels of high-density lipoprotein ("HDL") who have recently (within 7-90 days) experienced an acute coronary syndrome (myocardial infarction or unstable angina). These patients are at very high CVD risk despite standard of care treatment. The primary endpoint of the BETonMACE trial is designed to establish a relative risk reduction ("RRR") of Major Adverse Cardiac Events ("MACE"), narrowly defined as a single composite endpoint of cardiovascular death, non-fatal myocardial infarction or stroke. BETonMACE is an event-driven trial, and with recruitment complete, continues to accumulate MACE towards the required number.
"We are excited to receive feedback from the FDA that confirms the path forward for filing of an NDA for apabetalone, the first selective BET inhibitor for the treatment of high-risk cardiovascular disease. The FDA's feedback is similar to that received previously from European authorities. We are now focused on completing the BETonMACE study together with other activities required for NDA and Marketing Authorisation Application ("MAA") filings," stated Donald McCaffrey, President and CEO of Resverlogix.
Resverlogix is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra-terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with high-risk cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease treated with hemodialysis, neurodegenerative disease, Fabry disease, peripheral artery disease and other orphan diseases, while maintaining a well described safety profile. Apabetalone is currently being studied in a Phase 3 trial, BETonMACE, in high-risk CVD patients with type 2 DM and low levels of high-density lipoprotein (HDL). In BETonMACE approximately 11% of the participants have chronic kidney disease.
Resverlogix common shares trade on the Toronto Stock Exchange (TSX:RVX).
Follow us on Twitter: @Resverlogix_RVX
For further information please contact:
Or visit our website: www.resverlogix.com
This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. In particular, this news release includes forward looking information relating to the BETonMACE study, the filing and approval of an NDA and/or MAA, and the potential role of apabetalone in the treatment of CVD, DM, chronic kidney disease, end-stage renal disease treated with hemodialysis, neurodegenerative disease, Fabry disease, peripheral artery disease and other orphan diseases. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including those discussed in our Annual Information Form and most recent MD&A which are incorporated herein by reference and are available through SEDAR at www.sedar.com. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Resverlogix Corp via Globenewswire
Om Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
+1 212 401 8700http://www.nasdaqomx.com
NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.
Følg saker fra Nasdaq GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Nasdaq GlobeNewswire
Nasdaq Launches ESG futures in the Nordics15.10.2018 10:00 | Pressemelding
STOCKHOLM, Sweden, Oct. 15, 2018 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) today announced the launch of futures based on the recently launched OMXS30 ESG Responsible index (OMXS30ESG). The product is the first exchange listed and ESG compliant index future in the world. “In recent years we have seen institutions increase efforts to integrate sustainability into their investment strategies, with the Nordic region being in the forefront of this trend,” says Alessandro Romani, Head of European Equity Derivatives at Nasdaq. “Those looking to invest in a more sustainable way need more investment products based on established and liquid indexes. Our existing OMXS30 index future contract is among the most traded in Europe and we expect to see the same interest for the ESG version.” The OMXS30ESG Index was developed in cooperation with a number of leading Nordic asset managers, including Swedbank Robur. “At Swedbank, innovation and constant development are an important part of the business, a
Telix and ANMI Expand PSMA Imaging Partnership15.10.2018 00:00 | Pressemelding
MELBOURNE, Australia and LIÈGE, Belgium, Oct. 15, 2018 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX.TLX) (“Telix”, the “Company”), a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or “molecularly-targeted radiation” (MTR), today announced that it has expanded its partnership with Advanced Nuclear Medicine Ingredients SA (“ANMI”) for the 68Ga-HBED-CC-PSMA-11 (68Ga-PSMA) cold kit. The 68Ga-PSMA kit is developed by ANMI and commercialized by Telix for the US market where it is marketed as illumetTM . In response to considerable clinical interest in the illumetTM product, Telix has commenced scale-up manufacturing in the United States, following the recent filing of a drug master file (DMF) and the launch of several major clinical trials using the product, including the 750 patient VISION phase III trial (Endocyte, Inc.) and a 500-patient phase II study at Memorial Sloan Kettering C
Brookfield Asset Management 2018 Third Quarter Results Conference Call And Webcast12.10.2018 15:33 | Pressemelding
Date: Thursday, November 8, 2018 Time: 11:00 a.m. (Eastern Time) BROOKFIELD, NEWS, Oct. 12, 2018 (GLOBE NEWSWIRE) -- Brookfield Asset Management (NYSE:BAM)(TSX:BAM.A)(EURONEXT AMSTERDAM:BAMA): Third Quarter Conference Call You are invited to participate in Brookfield Asset Management’s 2018 Third Quarter Conference Call & Webcast on Thursday, November 8, 2018 at 11:00 a.m. (Eastern Time) to discuss with members of senior management our results and current business initiatives. These results will be released on November 8th before 7:00 a.m. (Eastern Time) and will be available following the release on our website at www.brookfield.com “News – Press Releases.” The Conference Call will also be Webcast live on our website, where it will be archived for future reference. To participate in the Conference Call, please dial (877) 255-3077 toll free in North America, or for overseas calls please dial (647) 252-4453 at approximately 10:50 a.m. The Conference Call will also be Webcast live at htt
Wasabi to Open its First European Data Center in Amsterdam11.10.2018 18:17 | Pressemelding
Provides Hot Cloud Storage Service for European Markets While Expanding Global Presence Boston, Oct. 11, 2018 (GLOBE NEWSWIRE) -- Wasabi, the hot cloud storage company, today announces plans to open its first European data center in Amsterdam, NL this coming December. With the addition of its latest data center, Wasabi will make its international debut by offering EU markets the lowest cost, highest performance cloud storage service available, now with very low latency for European customers. Wasabi’s hot cloud storage service enables companies to store their data at one-fifth the cost and 6x the speed of Amazon S3 with no additional egress fees. Wasabi customers will have more connectivity options, additional data center redundancy, automatic data replication and failover services, and faster speeds with close proximity to their own data centers. With its newest data center opening, Wasabi enables high-speed exchange between Wasabi storage and customer compute resources with multiple
SIMEX reduces trading commissions11.10.2018 16:50 | Pressemelding
American Retail Group Inc. (aka Simex Inc.) the public corporation organized in the State of Nevada, USA LAS VEGAS, Oct. 11, 2018 (GLOBE NEWSWIRE) -- (OTC: ARGB) -- SIMEX Inc. announces reducing trading commissions. Current trading commissions are set to 0.1% for both sides maker/taker which is 50% lower than before. Vassili Oxenuk, the President of SIMEX, said: "By reducing trading commissions we become more attractive to traders on the digital assets market." Trading commissions can be even reduced to 0%. SMX Token allows you to reduce the commissions when trading on the SIMEX Exchange. Commissions rate depending on the balance of the user's account*: 1 000 SMX: 0.075% Maker / 0.075% Taker. 5 000 SMX: 0.05% Maker / 0.05% Taker. 10 000 SMX: 0% Maker / 0% Taker. Contact information: Email: firstname.lastname@example.org Headquarters: 2300 West Sahara, Office 400, Las Vegas, 89102
Fortuna reports heavy seasonal rains caused an overflow in a contingency pond of the dry stack tailings facility at the San Jose Mine, Mexico11.10.2018 16:46 | Pressemelding
VANCOUVER, B.C., Oct. 11, 2018 (GLOBE NEWSWIRE) -- Fortuna Silver Mines Inc. (NYSE: FSM) (TSX: FVI) reports that in the early morning of October 8th, abnormally high rainfall caused a contingency pond to overflow at the dry stack tailings facility at the San Jose mine located in Oaxaca, Mexico. The contingency pond collects water from a ditch system at the dry stack facility designed to capture and manage rain water. The Company wants to emphasize that no industrial process water was discharged in this incident and that the San Jose operation uses a cyanide-free process to produce concentrate. The dry stack contingency pond’s holding capacity is 7,000 cubic meters and it is equipped with a 600 cubic meter per hour pumping capacity that was surpassed by the volume of rain fall. The overflow occurred for about two hours at approximately 4:00 am and resulted in the spill of approximately 1,500 cubic meters of water carrying sediment and minor amounts of fine tailings from the facility’s d
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom